Palopegteriparatide
Yorvipath
A prodrug that releases PTH(1-34) over time. Approved in the US for hypoparathyroidism in adults. The half-life here is the label’s apparent half-life of the PTH it releases.
- Half-life
- 2.5 d
- Out of system
- ~13 days
- Route
- Subcutaneous
- Level
- —
Class (Parathyroid hormone analog), half-life and route from the FDA label: Yorvipath (palopegteriparatide) injection (U.S. National Library of Medicine, DailyMed), checked 2026-09-26.
What Palopegteriparatide is used for
- Treatment of hypoparathyroidism in adults (FDA label); not studied for acute post-surgical hypoparathyroidism
How it's typically used
Prescription medicine in the US. The prescriber sets and adjusts the dose against blood calcium; the FDA label is cited on this page.
What to watch for
- Serious high and low blood calcium have both been reported
- Potential risk of osteosarcoma
- Orthostatic hypotension
- Hypersensitivity reactions, including anaphylaxis
Common questions
- What is the half-life of Palopegteriparatide?
- Palopegteriparatide has an approximate elimination half-life of 2.5 d.
- How long does Palopegteriparatide stay in your system?
- Roughly 97% of a dose has cleared after five half-lives — about ~13 days for Palopegteriparatide. That is the window that matters for washouts, bloodwork and surgery.
- How is Palopegteriparatide taken?
- Palopegteriparatide is typically administered by the subcutaneous route. Prescription medicine in the US. The prescriber sets and adjusts the dose against blood calcium; the FDA label is cited on this page.
- What are the risks of Palopegteriparatide?
- Serious high and low blood calcium have both been reported Potential risk of osteosarcoma Orthostatic hypotension Hypersensitivity reactions, including anaphylaxis
About Other research compounds
- What they are
- Nootropics, metabolic agents, and research compounds that don't fit the other classes.
- How they're run
- Route and schedule vary widely — check the individual entry.
- What to watch
- This is the least-characterised corner of the atlas. Read the full guide, and treat anything without published human data as exactly that.
Other other research compounds
Peptid AI is an educational and self-tracking tool — not a medical service, and not a vendor. Nothing here is medical advice, a prescription, or an endorsement. Doses reflect what is commonly reported in research literature; they are not recommendations. Many compounds listed are experimental, not approved for human use, and/or controlled substances that are illegal to possess without a prescription in many countries. Always consult a qualified physician before starting, changing, or stopping any protocol.